Advanced search
Publication Cover
Expert Review of Vaccines Volume 1, 2002 - Issue 4
Submit an article Journal homepage
119
Views
24
CrossRef citations to date
0
Altmetric
Review

Hepatitis B vaccine and risk of multiple sclerosis

Frank DeStefano Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop F34, Atlanta, GA 30341 3724, USA. [email protected]
,
Thomas Verstraeten GlaxoSmithKline Biologicals, Rixensart, Belgium.
&
Robert T Chen Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E61, Atlanta, GA 30333, USA. [email protected]
Pages 461-466 | Published online: 09 Jan 2014

References

  • Shaw FE Jr, Graham DJ, Guess HA et al Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. A117. I Epidemial 127(2), 337–352 (1988).
  • Herroelen L, de Keyser J, Ebinger G. Central- nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 338, 1174–1175 (1991).
  • •First case report of CNS demyelination after hepatitis B vaccine.
  • Trevisani F, Gattinara GC, Caraceni P et al. Transverse myelitis following hepatitis B vaccination. lipatol 19, 317–318 (1993).
  • Nadler JP. Multiple sclerosis and hepatitis B vaccination. Clin. Infect. Dis. 17, 928–929 (1993).
  • Tartaglino LM, Heiman-Patterson T, Friedman DP, Flanders AE. MR imaging in a case of postvaccination myelitis. Am. Neuroradial 16, 581–582 (1995).
  • Kaplanski G, Retomaz F, Durand J, Soubeyrand J. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype. j Neural. Neurosurg. PTchiatry 58, 758–759 (1995).
  • Albitar S, Bourgeon B, Genin R et al Bilateral retrobulbar optic neuritis with hepatitis B vaccination. Nephrol. Dial. Transplant. 12, 2169–2170 (1997).
  • Pirmohamed M, Winstanley P. Hepatitis B vaccine and neurotoxicity. Postgrad. Med. 73, 462–463 (1997).
  • Gout 0, Theodorou I, Liblau R, Lyon- Caen 0. Central nervous system demyelination after recombinant hepatitis B vaccination: report of 25 cases. Neurology 48, A424 (1997).
  • •Largest case series of CNS demyelination after hepatitis B vaccine.
  • Fledelius HC. Unilateral papilloedema after hepatitis B vaccination in a migraine patient. A case report including forensic aspects. Acta Ophthalmol. Scand. 77, 722–724 (1999).
  • Stewart 0, Chang B, Bradbury J. Simultaneous administration of hepatitis B and polio vaccines associated with bilateral optic neuritis. BE j Ophthalmol. 83, 1200–1201 (1999).
  • Anonymous. Hepatitis B Virus: A comprehensive strategy for eliminating transmission in the united states through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MAIWR40(RR-13), 1–19 (1999).
  • Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. N Engl. Med. 343, 938–952 (2000).
  • Gilden DH. Viruses and multiple sclerosis. JA/V/A 286, 3127–3129 (2001).
  • Owen RL, Dau PC, Johnson IKP, Spitler LE. Immunologic mechanisms in multiple sclerosis: exacerbation by type A hepatitis and skin test antigen. JAIVIA 244,2307–2309 (1980).
  • Moriabadi NF, Niewiesk S, Kruse N et al. Influenza vaccination in MS: Absence of T-cell response against white matter proteins. Neurology56,938–943 (2001).
  • Fujinami RS. Can virus infections trigger autoimmune diseases?' Autoimmutz 16, 229–234 (2001).
  • Olson JK, Croxford JL, Miller SD. Virus- induced autoimmunity: potential role of viruses in initiation, perpetuation and progression of T-cell-mediated autoimmune disease. Vitalimmunol 14, 227–250 (2001).
  • Rose NR. The role of infecton in the pathogenesis of autoimmune diseases. Semin. Iminunol 10,5–13 (1998).
  • Brocke S, Hausmann S, Steinman L, Wucherpfennig KW Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Semin. Iminunol 10,57–67 (1998).
  • Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230, 1043–1045 (1985).
  • Stratton K, Almario D, McCormick MC, (Eds). Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disotylets. National Academy Press, Washington, DC, USA (2002).
  • ••Comprehensive review by the IOM.Concludes that the evidence favors rejection of a causal association between heptitis B vaccination and MS.
  • Balinska MA. Laffaire hepatite B en France. Espirit276, 34–48 (2001).
  • Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: The situation in 2001.1 Merl Viral. 67(3), 433–439 (2002).
  • Touze E, Gout 0, Verdier-Taillefer MET, Lyon-Caen 0, Alperovitch A. [The first episode of central nervous system demyelinization and hepatitis B virus vaccination.] Rev Neural (Paris) 156(3), 242–246 (2000).
  • Touze E, Fourrier A, Rue-Fenouche C et al Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 21 (4), 180–186 (2002).
  • •French case-control study. Found nonsignificant relative risk of 1.6 for onset of MS within 12 months following hepatitis B vaccination.
  • Sturkenboom MCJM, Abenhaim L, Wolfson C, Roulet E, Heinzelf 0, Gout 0. Vaccinations, demyelination and multiple sclerosis study (VDAMS). Pharmacoepidemial Drug Safety 8, S170—S171 (1999).
  • Fourrier A, Begaud B, Alperovitch A et al Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases. BE J. Gun. Pharmacol 51(5), 489–490 (2001).
  • Soubeyrand B, Boisnard F, Bruel M et al [Central nervous system demyelinating disease following hepatitis B vaccination with GenHevac B. Review of ten years of spontaneous notifications (1989–1998)1. Besse Med 29(14), 775–780 (2000).
  • Gout 0. Vaccinations and multiple sclerosis. Neural. Sri. 22(2), 151–154 (2001).
  • Manuel C, Auquier P, San Marco JL. [The drama of blood contamination in France. An approach to public health]. Presse Merl 29(10), 547–552 (2000).
  • Monteyne P, Andre FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis? Vaccine 18(19), 1994-2001 (2000).
  • Aron E. Bull. Arad Nat! Med. 186(2), 361–368 (2002).
  • Levy-Bruhl D, Desenclos JC, Rebiere I, Drucker J. Central demyelinating disorders and hepatitis B vaccination: a risk- benefit approach for pre-adolescent vaccination in France. Vaccine 20(16), 2065–2071 (2002).
  • Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl. J. Merl 344, 327–332 (2001).
  • ••Large case-control study of US nurses.Found no increased risk of MS associated with hepatitis B vaccine.
  • Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat. Merl 5,964–965 (1999).
  • Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 355, 549–550 (2000).
  • Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccination and the risk of relapse in multiple sclerosis. N Engl. J. Merl 344,319–326 (2001).
  • ••Study of 643 MS patients. Found thathepatitis B vaccine did not cause disease relapse.
  • Halsey NA, Duds P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Pecliatc Infect. Dis.j 18,23–24 (1999).
  • Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis B vaccine. Vaccine 1,2473–2475 (1999).
  • Conseil superieurd 'hygiene publique. Avis du Conseil superieur d'hygiene publique de France relatif a la vaccination contre l'hepatite virale B. Bulletin Epidemiologique hebdomadally (24), 119 (2002).
  • Austad ED. Breast implant-related silicone granulomas: the literature and the litigation. Rast. Reconstc Surg. 109(5), 1724–1730 (2002).

Websites

  • Rothman KJ. Causal Inference. Chestnut Hill, MA: Epidemiology Resources, Inc., (1988).
  • Viral Hepatitis Prevention Board. Updated statement on hepatitis B vaccine safety. (June, 2000). Acessed on www.vhpb.org/on 10/08/02.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.